Please assess the completion status of the following clinical trial:

Trial Title: Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Signed informed consent form in accordance with institutional guidelines~* Histologically or cytologically confirmed primary CNS lymphoma documented by brain biopsy or cerebrospinal fluid or vitrectomy analysis~* CD20 positive disease~* Progressive or relapsed disease during or after completion of prior methotrexate-based chemotherapy~* Aged 18 months to 75 years~* Performance status ECOG 0-3 OR Karnofsky 30-100%~* Hematocrit at least 25% (transfusion or epoetin alfa allowed)~* Absolute granulocyte count at least 1,200/mm\^3~* Platelet count at least 100,000/mm\^3 OR at least lower limit of normal~* Bilirubin no greater than 2.0 times upper limit of normal~* Creatinine less than 1.8 mg/dL~* Calculated Creatinine clearance (CrCl) at least 50 mL/min~* Adequate cardiac function to tolerate general anesthesia~* Adequate pulmonary function to tolerate general anesthesia~* Available for follow-up for 1 year post therapy~* Fertile patients must use effective contraception for a minimum of 2 months before and during study participation~EXCLUSION CRITERIA:~* Radiographic signs of intra-cranial herniation and/or spinal block~* HIV positive~* Systemic lymphoma~* Positive serum HCG, pregnant or lactating~* Allergy to study agents~* Hepatitis B or hepatitis C positive

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).